Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642824 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL16946458 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL22127641 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL22127625 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL21993331 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL13973631 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL22672902 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL22127622 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL22127596 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL7151659 | 1.00 | CYP2D6 (0.69) | CYP2D6THRBHSD17B10CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | claimed |
| EP-4735463-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025000061-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801489-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112367987-A | Active agents and methods for their use in treating metabolic disorders and non-alcoholic fatty liver disease | 旗舰创业创新五公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200199166-A1 | ENZYME-DIRECTED IMMUNOSTIMULANT AND USES THEREOF | WASHINGTON STATE UNIVERSITY | 2020-06-25 | — | — | US | disclosed |
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | CYP2D6 1191/4885THRB 646/4885HSD17B10 157/4885 |
| US-20200199166-A1 | ENZYME-DIRECTED IMMUNOSTIMULANT AND USES THEREOF | ACHE, RNASE1, ENGASE | CYP2D6 398/4885THRB 4798/4885HSD17B10 1709/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | CYP2D6 1191/4885THRB 646/4885HSD17B10 157/4885 |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | CYP2D6 4145/4885THRB 1881/4885HSD17B10 602/4885 |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | CYP2D6 4145/4885THRB 1881/4885HSD17B10 602/4885 |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | CYP2D6 4145/4885THRB 1881/4885HSD17B10 602/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | CYP2D6 1191/4885THRB 646/4885HSD17B10 157/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | CYP2D6 1191/4885THRB 646/4885HSD17B10 157/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | CYP2D6 1191/4885THRB 646/4885HSD17B10 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.